NEUWAY Pharma GmbH« NEUWAY », a highly innovative biotechnology company specializing in the delivery of mRNA and other biotherapeutic drug molecules to the CNS and other tissues via its proprietary EnPC® drug-delivery technology, today announced two new appointments in its senior leadership team: Dr Oliver Ernst, formerly NEUWAY’s Chief Operating Officer, was promoted to Chief Executive Officer, and Dr Thomas Christoph was appointed as new Chief Development Officer.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220920005693/en/
Dr. Thomas Christoph, CDO (Photo: Business Wire)
Dr Ernst, who joined NEUWAY in 2019 as Chief Operating Officer and Managing Director, will now lead the company as CEO. NEUWAY co-founder Dr. Heiko Manninga will continue …
